{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T03:44:56Z","timestamp":1774928696074,"version":"3.50.1"},"reference-count":57,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Heart"],"accepted":{"date-parts":[[2021,7,1]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Diuretics reduce congestion in patients with heart failure with preserved ejection fraction (HFpEF). However, comparison of clinical effects across diuretic classes or combinations of diuretics in patients with HFpEF are not well described. Therefore, we sought to conduct a scoping review to map trial data of diuretic efficacy and safety in patients with HFpEF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Review methods and results<\/jats:title>\n                  <jats:p>We searched multiple bibliometric databases for published literature and ClinicalTrials.gov, and hand searched unpublished studies comparing different classes of diuretics to usual care or placebo in patients with HFpEF. We included randomised controlled trials or quasi-experimental studies. Two authors independently screened and extracted key data using a structured form. We identified 13 published studies on diuretics in HFpEF, with 1 evaluating thiazide use, 7 on mineralocorticoid receptor antagonists (MRAs) and 5 on sodium-glucose co-transporter 2 inhibitors (SGLT2i). There remain 17 ongoing trials evaluating loop diuretics (n=1), MRAs (n=5), SGLT2i (n=10) and a polydiuretic (n=1), including 2 well-powered trials of SGLT2i that will be completed in 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The limited number of published trials evaluating different classes of diuretics in patients with HFpEF have been generally small and short term. Ongoing and emerging trials of single or combination diuretics with greater power will be useful to better define their safety and efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Scoping review registration<\/jats:title>\n                  <jats:p>doi:10.18131\/g3-dejv-tm77.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/heartjnl-2021-319643","type":"journal-article","created":{"date-parts":[[2021,8,2]],"date-time":"2021-08-02T13:35:25Z","timestamp":1627911325000},"page":"593-605","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of diuretics in heart failure with preserved ejection fraction: a scoping review"],"prefix":"10.1136","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-7851","authenticated-orcid":false,"given":"Arushi","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7090-5601","authenticated-orcid":false,"given":"Anubha","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5228-8219","authenticated-orcid":false,"given":"Q. Eileen","family":"Wafford","sequence":"additional","affiliation":[{"name":"Galter Health Sciences Library, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjiv J","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Huffman","sequence":"additional","affiliation":[{"name":"George Institute for Global Health, Sydney, New South Wales, Australia"},{"name":"Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sadiya","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medicine (Cardiology), Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"},{"name":"Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,8,2]]},"reference":[{"key":"2025091923005967000_108.8.593.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfq121"},{"key":"2025091923005967000_108.8.593.2","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamainternmed.2015.0924","article-title":"A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010","volume":"175","author":"Gerber","year":"2015","journal-title":"JAMA Intern Med"},{"key":"2025091923005967000_108.8.593.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.064"},{"key":"2025091923005967000_108.8.593.4","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"2025091923005967000_108.8.593.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000509"},{"key":"2025091923005967000_108.8.593.6","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2016111178"},{"key":"2025091923005967000_108.8.593.7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ejhf.757","article-title":"Renal tubular resistance is the primary driver for loop diuretic resistance in acute heart failure","volume":"19","author":"Ter Maaten","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025091923005967000_108.8.593.8","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025091923005967000_108.8.593.9","unstructured":"Euctr de: Empagliflozin and its effect on heart failure in type 2 diabetes, 2016. Available: http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2016-000214-30-DE"},{"key":"2025091923005967000_108.8.593.10","unstructured":"Jprn U: canagliflozin heart failure with preserved ejection fraction study in type 2 diabetes mellitus, 2017. Available: http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000028668"},{"key":"2025091923005967000_108.8.593.11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1253\/circrep.CR-19-0049","article-title":"Rationale and Design of the CANONICAL Study - Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Canagliflozin for Heart Failure With Preserved Ejection Fraction With Type 2 Diabetes Mellitus","volume":"1","author":"Kasama","year":"2019","journal-title":"Circ Rep"},{"key":"2025091923005967000_108.8.593.12","unstructured":"Nct: effects of SGLT2 inhibition on the mechanisms of cardiac damage in the diabetic patient with HFpEF (CARDIA-STIFF) 2021."},{"key":"2025091923005967000_108.8.593.13","unstructured":"Nct: dapagliflozin in preserved ejection fraction heart failure (PRESERVED-HF) 2017."},{"key":"2025091923005967000_108.8.593.14","unstructured":"Nct: dapagliflozin evaluation to improve the lives of patients with preserved ejection fraction heart failure, 2018. Available: Https:\/\/clinicaltrials.gov\/show\/nct03619213"},{"key":"2025091923005967000_108.8.593.15","unstructured":"Nct: ertugliflozin triAl in diabetes with preserved or reduced ejeCtion fraction mEchanistic evaluation in heart failure, 2018. Available: Https:\/\/clinicaltrials.gov\/show\/nct03416270"},{"key":"2025091923005967000_108.8.593.16","unstructured":"Nct: DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction, 2019. Available: Https:\/\/clinicaltrials.gov\/show\/nct03877224"},{"key":"2025091923005967000_108.8.593.17","unstructured":"Nct: stratified treatment to ameliorate diastolic left ventricular stiffness in heart failure with preserved ejection fraction (STADIA-HFpEF) 2020."},{"key":"2025091923005967000_108.8.593.18","article-title":"Effects of empagliflozin on exercise capacity and LV diastolic function in HFpEF and type-2 diabetes mellitus: rationale and design of prospective intervention study","volume":"21","author":"Ovchinnikov","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2025091923005967000_108.8.593.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"2025091923005967000_108.8.593.20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2025091923005967000_108.8.593.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"2025091923005967000_108.8.593.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"2025091923005967000_108.8.593.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2030183"},{"key":"2025091923005967000_108.8.593.24","unstructured":"Nct: Polydiuretic therapy for heart failure with preserved ejection fraction and diabetes mellitus 2021."},{"key":"2025091923005967000_108.8.593.25","unstructured":"Singh AK , Sana S , Huffman MD . Eileen: Scoping review of efficacy and safety of low-dose diuretics for patients with heart failure with preserved ejection fraction. DigitalHub. Galter Health Sciences Library & Learning Center 2019."},{"key":"2025091923005967000_108.8.593.26","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/hr.2011.169","article-title":"Adding thiazide to a renin-angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension","volume":"35","author":"Ito","year":"2012","journal-title":"Hypertens Res"},{"key":"2025091923005967000_108.8.593.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2011.04.007"},{"key":"2025091923005967000_108.8.593.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.905"},{"key":"2025091923005967000_108.8.593.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.05.010"},{"key":"2025091923005967000_108.8.593.30","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025091923005967000_108.8.593.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.07.763"},{"key":"2025091923005967000_108.8.593.32","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1111\/jgs.14940","article-title":"Effect of spironolactone on exercise tolerance and arterial function in older adults with heart failure with preserved ejection fraction","volume":"65","author":"Upadhya","year":"2017","journal-title":"J Am Geriatr Soc"},{"key":"2025091923005967000_108.8.593.33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.016239","article-title":"Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial","volume":"9","author":"Shantsila","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025091923005967000_108.8.593.34","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of luseogliflozin on heart failure with preserved ejection fraction in patients with diabetes mellitus","volume":"9","author":"Ejiri","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2025091923005967000_108.8.593.35","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ehf2.12707","article-title":"Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2025091923005967000_108.8.593.36","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/bcp.14248","article-title":"Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure","volume":"86","author":"de Boer","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2025091923005967000_108.8.593.37","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","article-title":"Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes","volume":"42","author":"Abraham","year":"2021","journal-title":"Eur Heart J"},{"key":"2025091923005967000_108.8.593.38","doi-asserted-by":"crossref","unstructured":"Nassif ME , Qintar M , Windsor SL . Empagliflozin effects on pulmonary artery pressure in patients with heart failure: results from EMpagliflozin evaluation by measuring impact on hemodynamics in patients with heart failure (EMBRACE-HF) trial. Circulation 2021.","DOI":"10.1161\/CIRCULATIONAHA.120.052503"},{"key":"2025091923005967000_108.8.593.39","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006638","article-title":"Mechanistic effects of spironolactone on cardiovascular and renal biomarkers in heart failure with preserved ejection fraction: a TOPCAT Biorepository study","volume":"13","author":"Myhre","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2025091923005967000_108.8.593.40","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001937"},{"key":"2025091923005967000_108.8.593.41","unstructured":"Nct: TRANSFORM-HF: ToRsemide comparison with furoSemide FORManagement of heart failure (TRANSFORM-HF), 2018. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03296813"},{"key":"2025091923005967000_108.8.593.42","unstructured":"Chi CI: aldosterone antagonist delays the progression of heart failure with preserved ejection fraction: a randomised controlled clinical trial, 2016. Available: http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-INR-16008079"},{"key":"2025091923005967000_108.8.593.43","unstructured":"Euctr GB: effects of spironolactone in heart failure with preserved ejection fraction: measured by CMR, echo, Excercise capacity and quality of life Questionaire, 2014. Available: http:\/\/www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000867-10-GB"},{"key":"2025091923005967000_108.8.593.44","unstructured":"Nct: spironolactone in the treatment of heart failure (SPIRIT-HF 2018."},{"key":"2025091923005967000_108.8.593.45","unstructured":"Nct: spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction, 2016. Available: Https:\/\/clinicaltrials.gov\/show\/nct02901184"},{"key":"2025091923005967000_108.8.593.46","unstructured":"Nct: Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40% (FINEARTS-HF), 2020. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT04435626"},{"key":"2025091923005967000_108.8.593.47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/ejhf.811","article-title":"Exercise intolerance in heart failure with preserved ejection fraction: time to scrutinize diuretic therapy?","volume":"19","author":"Montero","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2025091923005967000_108.8.593.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00795-5"},{"key":"2025091923005967000_108.8.593.49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041818"},{"key":"2025091923005967000_108.8.593.50","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2021","journal-title":"Eur Heart J"},{"key":"2025091923005967000_108.8.593.51","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/ehf2.13236","article-title":"Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the canvas program","volume":"8","author":"Yu","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025091923005967000_108.8.593.52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1681\/ASN.20203110S121b","article-title":"Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis from DAPA-HF","volume":"31","author":"Kristensen S\u00f8","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2025091923005967000_108.8.593.53","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8807"},{"key":"2025091923005967000_108.8.593.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.034"},{"key":"2025091923005967000_108.8.593.55","article-title":"Abstract 11286: spironolactone lowers loop diuretic requirements without adversely affecting renal function and electrolyte balance in patients with heart failure and preserved ejection fraction: a TOPCAT trial analysis","volume":"138","author":"Kalogeropoulos","year":"2018","journal-title":"Circulation"},{"key":"2025091923005967000_108.8.593.56","first-page":"00082","article-title":"Association of baseline diuretic use with cardiovascular outcomes in patients with heart failure with preserved ejection fraction: a secondary analysis from TOPCAT","author":"Khan","year":"2021","journal-title":"J Card Fail"},{"key":"2025091923005967000_108.8.593.57","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008090","article-title":"Could a low-dose diuretic polypill improve outcomes in heart failure with preserved ejection fraction?","volume":"14","author":"Khan","year":"2021","journal-title":"Circ Heart Fail"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2021-319643","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T06:01:18Z","timestamp":1758348078000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2021-319643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,2]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,3,25]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1136\/heartjnl-2021-319643"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2021-319643","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"value":"1355-6037","type":"print"},{"value":"1468-201X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,2]]}}}